171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

“… 15 In addition, e x vivo evaluations and proof-of-concept phase I/II studies in patients with cancer showed that efti induces strong and sustainable primary (monocytes and dendritic cells) and secondary target cells (CD4+ and CD8+ T cells) activation if administered as monotherapy or together with chemotherapy. 15 , 16 , 17 , 18 , 19 Furthermore, efti injection resulted in increased C–X–C motif chemokine ligand 10 (CXCL10) chemokine plasma levels 14 days after injection. 19 Thus, a systemic type 1 T helper (TH1) cell environment may be induced over even months, as long as efti is administered.…”

“… 15 , 16 , 17 , 18 , 19 Furthermore, efti injection resulted in increased C–X–C motif chemokine ligand 10 (CXCL10) chemokine plasma levels 14 days after injection. 19 Thus, a systemic type 1 T helper (TH1) cell environment may be induced over even months, as long as efti is administered.…”

“…APC activators, such as efti, as well as Toll-like-receptor agonists or stimulator of interferon (IFN) genes, could activate innate immunity and increase the levels of T-cell attracting chemokines, such as CXCL9 or CXCL10, creating a so-called hot tumor microenvironment. 19 , 20 , 21 Therefore a strong rationale exists for combining efti with ICIs. This therapeutic approach is fundamentally different from previous ones that utilized anti-LAG-3 plus anti-PD-(L)1 antibodies (i.e.…”